For the year ending 2025-12-31, ONC had $1,970,900K increase in cash & cash equivalents over the period. $941,741K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 286,933 |
| Depreciation and amortization expense | 141,686 |
| Share-based compensation expense | 510,857 |
| Acquired in-process research and development | 691 |
| Amortization of research and development cost share liability | -101,095 |
| Impairment of equity investments | 75,626 |
| Loss on long-term investments | -596 |
| Non-cash interest expense | 14,872 |
| Deferred income tax expense | 9,469 |
| Gain on bms termination settlement | 0 |
| Other items, net | -2,953 |
| Accounts receivable | 164,954 |
| Inventories | 93,168 |
| Other assets | -37,164 |
| Accounts payable | 79,833 |
| Accrued expenses and other payables | 311,762 |
| Deferred revenue | 1,293 |
| Other liabilities | 18,968 |
| Net cash provided by (used in) operating activities | 1,127,580 |
| Purchases of property and equipment | 185,839 |
| Purchase of in-process research and development | 60,691 |
| Purchase of intangible assets | 20,000 |
| Purchase of long-term investments | 11,834 |
| Proceeds from sale or maturity of short-term investments | 3,446 |
| Other investing activities | 1,237 |
| Net cash (used in) provided by investing activities | -276,155 |
| Proceeds from sale of future royalties | 911,000 |
| Proceeds from long-term loan | 850,586 |
| Repayment of long-term loan | 35,680 |
| Proceeds from short-term loans | 233,676 |
| Repayment of short-term loans | 1,044,781 |
| Payments of debt issuance costs | 23,392 |
| Payments of withholding taxes from share-based awards | 24,195 |
| Proceeds from option exercises and employee share purchase plan | 196,281 |
| Repayment of sale of future royalties liability | 4,044 |
| Other financing activities | 0 |
| Net cash provided by financing activities | 1,059,451 |
| Effect of foreign exchange rate changes, net | 60,024 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 1,970,900 |
| Cash, cash equivalents, and restricted cash, beginning of year | 2,638,747 |
| Cash, cash equivalents, and restricted cash, end of year | 4,609,647 |
BeOne Medicines Ltd. (ONC)
BeOne Medicines Ltd. (ONC)